BioSpace News Archive

Business

Danaher Reports Third Quarter 2023 Results

Danaher Corporation announced results for the third quarter ended September 29, 2023.

October 24, 2023
·
30 min read
Genetown

Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis

Ocean Biomedical, Inc., announced that its Chief Scientist, Jonathan Kurtis MD, PhD has received the prestigious Falk Medical Research Trust Transformational Award to advance a new class of anti-malarial drug candidates.

October 24, 2023
·
7 min read
Business

3M Reports Third Quarter 2023 Results; Company Increases Full Year Adjusted Earnings and Cash Flow Expectations

Q3 results reflect strong operational execution, restructuring actions, and proactive spending discipline.

October 24, 2023
·
11 min read
Lone Star Bio

Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics

Caris Life Sciences® announced a new agreement with Moderna in support of Moderna’s oncology and novel therapeutics initiatives.

October 24, 2023
·
6 min read
Business

Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023

Sage Therapeutics, Inc. announced that it will host a live webcast on Tuesday, November 7, 2023 at 8:00 a.m. ET to review third quarter 2023 financial results and discuss recent business updates.

October 24, 2023
·
1 min read
Genetown

KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference

KalVista Pharmaceuticals, Inc. announced the presentation of a novel analysis characterizing hereditary angioedema attacks occurring in patients receiving long-term prophylaxis treatments at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference in Singapore.

October 24, 2023
·
4 min read
Business

ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023

ADC Therapeutics SA announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m. ET to report financial results for the third quarter 2023 and provide business updates.

October 24, 2023
·
4 min read
Policy

MeMed awarded US BARDA contract to demonstrate clinical utility of the FDA-cleared MeMed BV® test for distinguishing bacterial from viral infections

MeMed is pleased to announce that it has been awarded a contract valued at $727,799 by the Division of Research, Innovation, and Ventures of the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority.

October 24, 2023
·
2 min read
Drug Development

Sparrow Pharmaceuticals Doses First Patient in Phase 2 ACSpire Study of SPI-62 for Autonomous Cortisol Secretion

Sparrow Pharmaceuticals today announced that the first patient has been dosed in the Phase 2 ACSpire study (NCT number: NCT05436639 ) of SPI-62.

October 24, 2023
·
3 min read
Drug Development

Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 / 2 Clinical Trial

Aurion Biotech today announced that it has dosed the first subject in its Phase 1 / 2 U.S. clinical trial (ABA-1, CLARA) of AURN001.

October 24, 2023
·
3 min read